Research Article

Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy

Table 3

Ventricular function at the time of cardiotoxicity by chemotherapy agent received.

(+) Anthracycline
(−) Anthracycline

Time to toxicity in months*5 (5)7.5 (5.7)
Left ventricle
 Baseline EF by
  MUGA (%)
62 ± 660 ± 3
 Cardiotoxicity EF
  by MUGA (%)
48 ± 447 ± 4
 Cardiotoxicity EF
  by ECHO (%)
46 ± 644 ± 5
 Cardiotoxicity
  GLS
−15.5 ± 2.5−15.7 ± 2.5
Right ventricle
 Baseline EF
  by MUGA (%)
46 ± 443 ± 3
 Cardiotoxicity EF
  by MUGA (%)
44 ± 640 ± 5
 Cardiotoxicity
  FAC by ECHO
  (%)
42 ± 843 ± 5
 Cardiotoxicity
  RVFWLS
−24.1 ± 3.9−27.4 ± 4.6
 Cardiotoxicity
  RVGLS
−20.4 ± 2.8−22.8 ± 3.2

Median (IQR) onset of cardiotoxicity which occurred after initiation of TZM therapy in 21 patients; in 1 patient toxicity occurred after 3 months from the start of chemotherapy. Abbreviations as per Table 2.